S-1: Kestra Medical Technologies Files for IPO, Aiming to Disrupt Wearable Defibrillator Market

Kestra Medical Technologies, a wearable medical device company, has filed an S-1 registration statement for an initial public offering (IPO) to further commercialize its Cardiac Recovery System platform and ASSURE WCD.

Summary

• Kestra Medical Technologies, Ltd. has filed a Form S-1 registration statement with the SEC for an IPO.
• The company is focused on transforming cardiovascular disease treatment using its Cardiac Recovery System platform, including the ASSURE WCD.
• The ASSURE WCD is a next-generation wearable cardioverter defibrillator designed to enhance patient comfort and compliance.
• The IPO aims to raise capital to scale the commercial organization, fund R&D, and for general corporate purposes.
• The company's revenue for the six months ended October 31, 2024, was $27.5 million, a 190% increase compared to the same period in 2023.
• Kestra estimates its annual addressable market in the U.S. to be approximately $10 billion and $14 billion outside the U.S.
• The company is an emerging growth company and a smaller reporting company, which allows for reduced reporting requirements.
• Bain Capital will control approximately % of the company's common shares after the offering, making Kestra a controlled company.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting strong revenue growth and a large addressable market. However, it also acknowledges the company's history of net losses and the risks associated with operating in a competitive and regulated industry.

Positives

• Significant revenue growth of 190% in the first six months of 2024.
• Large estimated addressable market in the U.S. and internationally.
• Clinical data supports the efficacy and safety of the ASSURE WCD.
• The ASSURE WCD is designed to improve patient comfort and compliance compared to existing devices.
• The company has secured Medicare Provider Number enabling them to bill Medicare for reimbursement for their ASSURE WCD.

Negatives

• The company has a history of net losses and an accumulated deficit.
• The company's financial statements include an explanatory paragraph describing the existence of substantial doubt about the company's ability to continue as a going concern.
• The company is dependent on the success of its ASSURE WCD.
• The company will be a controlled company post-IPO, which reduces certain corporate governance requirements.

Risks

• Limited operating history makes it difficult to evaluate the business's likelihood of success.
• Recurring losses from operations raise substantial doubt about the company's ability to continue as a going concern.
• The company is dependent on healthcare providers and patients adopting its solutions.
• Estimates of market size and growth may be inaccurate.
• Commercial success depends on coverage and adequate reimbursement levels from governmental authorities and health insurers.
• The company depends on a limited number of third-party suppliers and contract manufacturers.
• Billing for the company's products is complex.
• Competitors may develop more effective products or gain greater market acceptance.
• The company has identified material weaknesses in its internal control over financial reporting.
• Third parties may assert intellectual property infringement claims.
• Changes in the regulatory environment may increase costs.
• Failure to comply with healthcare regulations could result in substantial penalties.
• Bain Capital controls the company, and its interests may conflict with those of other shareholders.

Future Outlook

The company expects to continue incurring losses for the next several years and anticipates further penetration and growth of the WCD market, driven by increased awareness and education about WCD therapy, the expanded launch of its innovative and comprehensive solution, and the rapidly growing heart failure population.

Management Comments

• The ASSURE WCD was purpose-built to enhance patient comfort and compliance and directly address the key barriers to adoption associated with the only other commercially available WCD.
• We believe our Cardiac Recovery System platform addresses serious unmet needs in the cardiac patient population and has the potential to disrupt and grow the market which has been limited to a single solution for more than 20 years.

Industry Context

The WCD market has been dominated by a single player for over 20 years. Kestra's entry with the ASSURE WCD aims to disrupt this market by addressing limitations of existing devices, such as patient comfort and false alarm rates. The company's integrated digital solutions and services further differentiate it from competitors.

Comparison to Industry Standards

• The ASSURE WCD reports a 6% false alarm rate, significantly lower than the 46% reported for the competitor device (LifeVest by ZOLL Medical Corporation).
• The ASSURE WCD delivers a 170 joule shock, compared to the 150 joule shock delivered by the LifeVest WCD.
• The ASSURE WCD offers gender-specific garment designs, addressing a comfort issue not met by the unisex LifeVest WCD.
• The VEST trial, which evaluated the LifeVest WCD, showed that a significantly lower percentage of patients died when they were wearing the WCD than when they were not.

Related Party Transactions

• West Affum Holdings, L.P. will contribute all its equity interests in West Affum Intermediate Holdings to Kestra Medical Technologies, Ltd., the issuer in this offering in exchange for common shares of Kestra Medical Technologies Ltd., thereby making Kestra Medical Technologies, Ltd. the top parent company of West Affum Intermediate Holdings and all of its subsidiaries.
• West Affum Holdings, L.P. will distribute to holders of all of its Class A common units and incentive units (including a third-party investor who will receive Class A common units in West Affum Holdings, L.P. immediately prior to the distribution in exchange for its equity interests in West Affum Holdings Designated Activity Company) common shares of Kestra Medical Technologies, Ltd., in consideration for the redemption of such holders interests in West Affum Holdings, L.P.
• Certain warrants issued by West Affum Holdings, L.P. will be canceled, and Kestra Medical Technologies, Ltd. will issue new warrants to purchase an aggregate of common shares of Kestra Medical Technologies, Ltd., with warrants with respect to , and common shares having exercise prices of $ , $ and $ , respectively, assuming an initial public offering price of $ per share, the midpoint of the price range set forth on the cover page of this prospectus.
• West Affum Holdings, L.P. will continue to hold common shares of Kestra Medical Technologies, Ltd. for the benefit of the holders of common units in West Affum Holdings, L.P., including an affiliate of Bain Capital, until such time that such common shares are distributed by West Affum Holdings, L.P. to the remaining partners of West Affum Holdings, L.P., which is currently expected to occur approximately nine months after the consummation of this offering (the Post-IPO Distribution).

Stakeholder Impact

• Shareholders will experience dilution as a result of the IPO.
• Employees may benefit from stock options and increased job opportunities.
• Patients may benefit from improved access to the ASSURE WCD.
• Healthcare providers may have a new treatment option for patients at risk of SCA.

Next Steps

• The company intends to scale up its commercial organization.
• The company plans to continue its payor engagement to broaden coverage and increase reimbursement.
• The company will pursue expansion in international markets.
• The company will strategically pursue adjacent markets with new product offerings and differentiated services.

Key Dates

Keywords

Wearable Cardioverter Defibrillator, Cardiac Arrest, Medical Device, Digital Healthcare, Initial Public Offering, Cardiovascular, Defibrillator, Kestra